1-17 of 17
Daniel W. Pierce
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BMS-986458 a Potential First-in-Class, Highly Selective, Potent and Well Tolerated BCL6 Ligand Directed Degrader (LDD) Demonstrates Multi-Modal Anti-Tumor Efficacy for the Treatment of B-Cell Non-Hodgkin's Lymphoma

Lynda Groocock, Gauri Deb, Jinyi Zhu, Jim Gamez, Paola Castiglioni, Manuel Sanchez-Castillo, Justin Schumacher, Alicia Benitez Rondan, Diana Jankeel, Karla Martinez-Garcia, Scott Wood, Andy Christoforou, Carla Guarinos, Wei Zhang, Rama Krishna Narla, Christoph W. Zapf, Soraya Carrancio, Daniel W. Pierce, Mark Rolfe, Neil Bence, Antonia Lopez-Girona, Deborah S. Mortensen
Journal: Blood
Blood (2024) 144 (Supplement 1): 957.
https://doi.org/10.1182/blood-2024-210951
Published: 2024
Journal Articles

Synergistic Activity of BMS-986397, a First-in-Class a Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Targeting Casein Kinase 1α (CK1α), in Combination with Venetoclax and/or Azacitidine in Preclinical Models of Acute Myeloid Leukemia (AML)

Carmen Jimenez, Jose Francisco Lopez, Estela Garcia, Laura Diaz Regalado, Alejandro Panjkovich, Sophie Peng, Rama Krishna Narla, Noelia Purroy, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio
Journal: Blood
Blood (2024) 144 (Supplement 1): 1395.
https://doi.org/10.1182/blood-2024-210023
Published: 2024
Journal Articles

BMS-986397, a First-in-Class Molecular Glue Degrader of Casein Kinase 1α (CK1α) for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Harboring Functional TP53

Carmen Jimenez, Sophie Peng, Rama Krishna Narla, Joshua Baughman, Scott Wood, Jean Lu, Noelia Purroy, Gina Yanochko, Mark Nagy, Gang Lu, Mark Rolfe, Daniel W. Pierce, Soraya Carrancio
Journal: Blood
Blood (2024) 144 (Supplement 1): 4142.
https://doi.org/10.1182/blood-2024-209924
Published: 2024
Journal Articles

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Soraya Carrancio, Jessica Voetsch, Alberto Risueño, Carla Guarinos, Siddhesh Kulkarni, Mandeep Takhar, Matthew E. Stokes, Bérengère de Moucheron, Laura Furman, Julio C. Chavez, Jean-Marie Michot, Loretta Nastoupil, Daniel W. Pierce, Danielle Greenawalt, Michael Pourdehnad
Journal: Blood
Blood (2024) 144 (Supplement 1): 3104.
https://doi.org/10.1182/blood-2024-203139
Published: 2024
Journal Articles

Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models

Bruno Paiva, Bonny Gaffney, Kelven Burnett, Paola Castiglioni, Michael Angelo, Daniel W. Pierce, Isaac W. Boss
Journal: Blood
Blood (2022) 140 (Supplement 1): 7054–7055.
https://doi.org/10.1182/blood-2022-157987
Published: 2022
Journal Articles

Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing

Bonny Gaffney, Yu Shi, Petrus de Jong, Manuel Sanchez, Celia Fontanillo, Antonia Lopez-Girona, Isaac W. Boss, Antonina Kurtova, Soraya Carrancio, Lilly Wong, Daniel W. Pierce
Journal: Blood
Blood (2022) 140 (Supplement 1): 7108–7109.
https://doi.org/10.1182/blood-2022-157939
Published: 2022
Journal Articles

Association of Immune Dynamics and Treatment Outcome in Patients (pts) with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) Treated with the Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent CC-99282

Soraya Carrancio, Wen-Chi Chou, Alberto Risueño, Carla Guarinos, Gonzalo Lopez, Jean-Marie Michot, Loretta J. Nastoupil, Julio Chavez, Cecilia Carpio, Silvia Ferrari, Tatyana A. Feldman, Daniel Morillo Giles, Antonio Pinto, Danielle Greenawalt, Daniel W. Pierce, Michael Pourdehnad
Journal: Blood
Blood (2022) 140 (Supplement 1): 6455–6457.
https://doi.org/10.1182/blood-2022-159585
Published: 2022
Journal Articles

Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models

Daniel W. Pierce, Tsun-Wen Sheena Yao, Emily Pace, Hongbin Wang, Pierre Flandin-Blety, Alicia Benitez, Carla Guarinos, Matthew Hoffmann, Soraya Carrancio, Jinhong Fan, Michael Pourdehnad
Journal: Blood
Blood (2021) 138 (Supplement 1): 3330.
https://doi.org/10.1182/blood-2021-147160
Published: 2021
Journal Articles

CC-99282 is a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent with Enhanced Tumoricidal Activity in Preclinical Models of Lymphoma

Soraya Carrancio, Lynda Groocock, Preethi Janardhanan, Diana Jankeel, Ryan Galasso, Carla Guarinos, Rama K. Narla, Matthew Groza, Jim Leisten, Daniel W. Pierce, Mark Rolfe, Antonia Lopez-Girona
Journal: Blood
Blood (2021) 138 (Supplement 1): 1200.
https://doi.org/10.1182/blood-2021-148068
Published: 2021
Journal Articles

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Christine Surka, Liqing Jin, Nathan Mbong, Chin-Chun Lu, In Sock Jang, Emily Rychak, Derek Mendy, Thomas Clayton, Elizabeth Tindall, Christy Hsu, Celia Fontanillo, Eileen Tran, Adrian Contreras, Stanley W. K. Ng, Mary Matyskiela, Kai Wang, Philip Chamberlain, Brian Cathers, James Carmichael, Joshua Hansen, Jean C. Y. Wang, Mark D. Minden, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, Mark Rolfe, Antonia Lopez-Girona, John E. Dick, Gang Lu
Journal: Blood
Blood (2021) 137 (5): 661–677.
https://doi.org/10.1182/blood.2020008676
Published: 2021
Includes: Supplemental data
Journal Articles

Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Lilly Wong, Manisha Lamba, María Dolores Jiménez Nuñez, Daniel Bauer, Paul G. Richardson, MD, Nizar J. Bahlis, MD, Annette J. Vangsted, Karthik Ramasamy, Suzanne Trudel, Joaquín Martínez-Lopez, María-Victoria Mateos, Paula Rodriguez-Otero, MD PhD, Sagar Lonial, MD FACP, Rakesh Popat, Albert Oriol, Chatchada Karanes, Robert Z. Orlowski, MDPhD, Jesus G. Berdeja, MD, Michael Pourdehnad, Daniel W. Pierce
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–48.
https://doi.org/10.1182/blood-2020-137161
Published: 2020
Journal Articles

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Antonia Lopez-Girona, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka, Chin-Chun Lu, Mary Matyskiela, Gody Khambatta, Lilly Wong, Joshua Hansen, Daniel W. Pierce, Brian E. Cathers, James Carmichael
Journal: Blood
Blood (2019) 134 (Supplement_1): 1812.
https://doi.org/10.1182/blood-2019-124338
Published: 2019
Journal Articles

CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma

Lilly Wong, Rama Krishna Narla, Jim Leisten, Daniel Bauer, Matthew Groza, Bonny Gaffney, Courtney G. Havens, Justin Choi, Jack Houston, Antonia Lopez-Girona, Joshua Hansen, Brian E. Cathers, James Carmichael, Daniel W. Pierce
Journal: Blood
Blood (2019) 134 (Supplement_1): 1815.
https://doi.org/10.1182/blood-2019-124345
Published: 2019
Journal Articles

Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Jinhong Fan, Hongbin Wang, Suzana Couto, Tsun-Wen Sheena Yao, Geoffrey L. Uy, MD, Amer M. Zeidan, MBBS, MHS, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Tonia J. Buchholz, Michael Pourdehnad, Daniel W. Pierce
Journal: Blood
Blood (2019) 134 (Supplement_1): 2547.
https://doi.org/10.1182/blood-2019-124291
Published: 2019
Journal Articles

Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study

Geoffrey L. Uy, MD, Mark D. Minden, Pau Montesinos, Daniel J. DeAngelo, Jessica K. Altman, Jamie Koprivnikar, MD, Paresh Vyas, MD PhD, Yngvar Fløisand, María Belén Vidriales, Bjørn Tore Gjertsen, Jordi Esteve, Tonia J. Buchholz, Suzana Couto, Jinhong Fan, Bishoy Hanna, Li Li, Daniel W. Pierce, Kristen Hege, Michael Pourdehnad, Amer M. Zeidan, MBBS, MHS
Journal: Blood
Blood (2019) 134 (Supplement_1): 232.
https://doi.org/10.1182/blood-2019-123966
Published: 2019
Journal Articles

A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1

Liqing Jin, MD, Nathan Mbong, Stanley W.K. Ng, PhD, Jean C.Y. Wang, MD, Mark D. Minden, MD PhD, Jinhong Fan, Daniel W. Pierce, Michael Pourdehnad, MD, John E. Dick, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3940.
https://doi.org/10.1182/blood-2019-128450
Published: 2019
Journal Articles

Target Engagement, Pathway Inhibition, and Efficacy Of The Bruton’s Tyrosine Kinase (Btk) Inhibitor CC-292

Daniel W Pierce, Sabine Ponader, PhD, Kumudha Balakrishnan, Varsha Gandhi, PhD, William G. Wierda, MD, Susan O'Brien, MD, Carla Heise, PhD, Mariana Nacht, PhD, Sharon Aslanian, Xiping Liu, Sean Hong, Shijuan Wu, Marianna Zavodovskaya, MS, Jeffrey Marine, Evelyn Barnett, Pilar Nava-Parada, Jay Mei, MD, Rajesh Chopra, MD, Jan A. Burger, MD, PhD, Juswinder Singh
Journal: Blood
Blood (2013) 122 (21): 4169.
https://doi.org/10.1182/blood.V122.21.4169.4169
Published: 2013